Navigation Links
FDA Panel Supports Anemia Drugs for Cancer Patients
Date:3/13/2008

But adds strong caveats on their use for some undergoing chemo

THURSDAY, March 13 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel voted Thursday to recommend continued use of blood-boosting drugs for cancer patients on chemotherapy, with the caveat that certain cancer sufferers should steer clear of the medications.

According to the Wall Street Journal, the panel voted 13-1 for letting Amgen Inc. continue selling Epogen and Aranesp and Johnson & Johnson continue selling Procrit. But the panel voted 11-2 to recommend against the drugs' use for cancer patients who are likely to be cured. And, in a 9-5 vote, the panel also recommended the drugs not be used in patients with breast or head and neck cancer.

FDA briefing documents filed this week before the meeting showed there are eight clinical trials that now suggest these widely used medications actually speed the growth of tumors and shorten the lives of cancer victims. Known as erythropoiesis-stimulating agents (ESAs), they work by stimulating red blood cell production.

"Whereas at the time of approval safety concerns were theoretical, there is now mounting evidence of documented effects on survival, tumor progression, and thrombotic events which require a re-assessment of the net benefits of this class of drugs," FDA officials stated. "Based on data provided to FDA, there is no evidence that ESAs improve quality of life or cancer outcomes."

Thursday's meeting is only the latest in a long string of FDA actions concerning the potential dangers of these drugs since their approval in the early 1990s.

This isn't the only group of patients using ESAs that concerns the FDA. In kidney patients, past research has found that if these drugs are used to raise hemoglobin levels above 12 grams per deciliter of blood, the risk of death increases.

The growing body of evidence led the FDA to have the drugs' manufactur
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Panel Weighs Safety of Anemia Drugs for Cancer Patients
2. Nasdaq Hearings Panel Grants TeamStaffs Request for Continued Listing Subject to a Reverse Stock Split
3. Is Cancer Community in Alignment About Cure and Costs? NCCN Conference Panel Asks
4. CDC Panel Urges Extending Flu Vaccine Coverage for Kids
5. Key Business, Labor and Academic Experts Join Stop Obesity Alliance Panel to Present Policy Perspectives and Recommendations to Reshape The Union
6. FDA Panel OKs 3 New Flu Strains for Next Years Vaccine
7. VA Creating Advisory Panel on Rural Health
8. Penn childhood obesity researchers panelists at AAAS Town Hall Event
9. Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
10. Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses
11. Decongestant in OTC Cold Remedies Effective: FDA Panel
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Supports Anemia Drugs for Cancer Patients
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Cell ... The report then explores global and China’s top ... capacity, Production value, and market share etc. The ...
(Date:8/30/2014)... Hundreds of Byetta lawsuits ( http://www.byettalawsuit.com ... forward in U.S. courts, Bernstein Liebhard LLP reports. According ... 31, 2014, Byetta and Bydureon (an extended-release version of ... that allege the drugs caused pancreatitis, pancreatic cancer and ... claims are pending in a multidistrict litigation underway in ...
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... The diagnosis of multiple sclerosis using the magnetic resonance ... the new findings// published by the BMJ. ... the National Institute for Health and Clinical Excellence (NICE) ... sclerosis. Although its accuracy has been assessed, the evidence ...
... ministry have denied the presence of any bird flu infection ... flu,' said Jose Angel del Valle, the ministry's animal health ... in the U.S. commodities markets, leading to a reduction in ... the death of a duck, in the town of Nogales, ...
... government will donate $35,700 to a clinic here ... ,The donation, in Australian dollars, was announced ... ,"The donation again demonstrates the Australian ... she said. ,"By funding this clinic, ...
... of Health in China has revealed that just over 67 ... HIV/AIDS//. ,This survey was conducted recently by a research ... from 1,919 respondents in 24 colleges of 19 cities.,The results ... aware of how HIV/AIDS is transmitted and 75.6 per cent ...
... non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs, ... NEXIUM? (esomeprazole magnesium). // These results were from ... the April 2006 edition of the American Journal ... such as ibuprofen, naproxen and aspirin, and newer ...
... Nitish Kumar is all for a giving a boost to ... tomato and green vegetables// at their official residence, he wants ... farming. ,Nitish Kumar comes from a family with ... practitioner in his home district of Nalanda. Even today Nitish's ...
Cached Medicine News:Health News:MRI Scan Insufficient For Diagnosing Multiple Sclerosis 2Health News:Patients on NSAIDS have reduced gastric ulcers risk by Nexium? 2
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... North America Aesthetic Lasers and Energy ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America Aesthetic ... Summary GlobalData,s new report, "North America ... 2020", provides key market data on the North ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... The Blumenthal,Cancer Center at Carolinas Medical Center (CMC) ... in a study that could lead to individualized,treatments ... first hospital system,outside Moffitt,s home state of Florida ... CMC will enroll more than 2,300 patients in,the ...
... PCOP ), an innovator in the discovery and ... completion of recruitment,in the company,s multi-center Phase 2a ... product candidate. The objective of the Phase,2a randomized, ... and safety of 200 and 500 mg of ...
Cached Medicine Technology:CMC, Moffitt Partner to Study Cancer 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 4
... TheraSeed® Pd-103 implant is a combination of ... visibility that makes TheraSeed® treatment an ideal ... be confident that every TheraSeed® implant order ... which is required by clinicians who must ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Medicine Products: